These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 30450524

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I, Frutos Pérez-Surio A, Alcácera MA, Andrés R, Salvador MDT.
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [Abstract] [Full Text] [Related]

  • 4. Responses of Blood System to Doxorubicin/Docetaxel Chemotherapy in Patients with Breast Cancer.
    Goldberg VE, Polyakova TY, Popova NO, Vysotskaya VV, Simolina EI, Dudnikova EA, Goncharova NM, Belevich YV, Grigor'ev EG, Goldberg AV, Dygai AM.
    Bull Exp Biol Med; 2019 Dec; 168(2):275-279. PubMed ID: 31782001
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
    Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH.
    Support Care Cancer; 2017 Feb; 25(2):505-511. PubMed ID: 27709313
    [Abstract] [Full Text] [Related]

  • 7. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [Abstract] [Full Text] [Related]

  • 8. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J.
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA, O'Brien S, Thomas DA, Pierce SA, Lam TP, Kantarjian HM.
    Cancer; 2002 Jan 15; 94(2):285-91. PubMed ID: 11900213
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of granulocytopoiesis-stimulating activity of immobilized granulocytic colony-stimulating factor in cytostatic myelosuppression.
    Dygai AM, Vereshchagin EI, Zhdanov VV, Zyuz'kov GN, Ermakova NN, Madonov PG, Miroshnichenko LA, Minakova MY, Simanina EV, Stavrova LA, Udut EV, Firsova TV, Khrichkova TY.
    Bull Exp Biol Med; 2009 Jul 15; 148(1):49-53. PubMed ID: 19902095
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
    Livi L, Meattini I, de Luca Cardillo C, Scotti V, Agresti B, Franzese C, Sanchez L, Nori J, Bertocci S, Cassani S, Bianchi S, Cataliotti L, Biti G.
    J Chemother; 2011 Feb 15; 23(1):36-9. PubMed ID: 21482493
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP-doxorubicin-vinorelbine-cyclophosphamide-fluorouracil) and granulocyte colony-stimulating factor in breast cancer.
    Charrier S, Chassagne J, Curé H, Bay JO, Communal Y, Portefaix G, Ferrière JP, Bétail G, Plagne R, Chollet P.
    Bone Marrow Transplant; 1998 Nov 15; 22(9):845-51. PubMed ID: 9827811
    [Abstract] [Full Text] [Related]

  • 18. [Cancer of the breast in young women: should chemotherapy be intensified?].
    Piccart MJ.
    Pathol Biol (Paris); 1992 Nov 15; 39(9):843-4. PubMed ID: 1371604
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M, Esteves S, André R, Isidoro M, Moreira A.
    Support Care Cancer; 2016 Feb 15; 24(2):597-603. PubMed ID: 26111956
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.